Results 71 to 80 of about 4,626,170 (385)

Neoadjuvant therapy for breast cancer [PDF]

Journal of Surgical Oncology, 2010
AbstractThe past few decades have seen an increase in both the role and the complexity of neoadjuvant therapy for breast cancer. Neoadjuvant therapy was initially described as systemic chemotherapy for inflammatory or locally advanced breast cancer but now entails a combination of chemotherapy, endocrine therapy, and targeted therapy.
Stephen F. Sener, Christy A. Russell, Kathy Yao, Laleh G. Melstrom, Stephen V. Liu   +4 more
openaire   +3 more sources

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source

Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate.

PLoS ONE, 2019
OBJECTIVES:Complete resection of thymic neoplasms is important for achieving a favorable prognosis; however, the efficacy of neoadjuvant therapy remains controversial.
Jee Won Suh, Seong Yong Park, Chang Young Lee, Seung Hwan Song, Dae Joon Kim, Hyo Chae Paik, Kyoung Young Chung, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Jin Gu Lee   +10 more
doaj   +1 more source

Neoadjuvant Treatment of Borderline Resectable Pancreatic Cancer

Zhongliu Fangzhi Yanjiu, 2022
Borderline resectable pancreatic ductal adenocarcinoma accounts for approximately 20% of newly diagnosed pancreatic cancer patients. This type of adenocarcinoma is between resectable and unresectable. It has a high degree of heterogeneity and features in
CHEN Zegang, WANG Yongbing, OU Tao
doaj   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

F-18-FDG and C-11-choline positron emission tomography in human esophago-gastric cancer : prediction of response to therapy [PDF]

, 2010
Peer reviewedPublisher ...
Hammonds, Solveig, McAteer, Dympna, Nicolson, Marianne, Park, Kenneth, Schweiger, Lutz, Sheehan, Margaret, Smith, Timothy, Suttie, Stuart, Welch, Andrew   +8 more
core   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Impacts of neoadjuvant therapy on the number of dissected lymph nodes in esophagogastric junction cancer patients

BMC Gastroenterology, 2023
Background Neoadjuvant therapy favors the prognosis of various cancers, including esophagogastric junction cancer (EGC). However, the impacts of neoadjuvant therapy on the number of dissected lymph nodes (LNs) have not yet been evaluated in EGC.
Qi Wang, Jin-tong Ge, Hua Wu, Sheng Zhong, Qing-quan Wu   +4 more
doaj   +1 more source

Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities [PDF]

, 2017
© 2017 The Author(s). Anti-cancer therapies including chemotherapy aim to induce tumour cell death. Cell death introduces alterations in cell morphology and tissue micro-structures that cause measurable changes in tissue echogenicity.
A Ahmed, A Guimond, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, B Banihashemi, B Fisher, B Ganeshan, BS Garra, BS Pio, BT Hennessy, C-P Chou, D Sethi, DA Mankoff, EJ Feleppa, EJ Feleppa, F Tixier, FJ Esteva, FL Lizzi, FT D’Astous, G Berger, G Minckwitz von, GJ Czarnota, GJ Czarnota, GN Hortobagyi, H Haibo, H Tadayyon, H Tadayyon, H Tadayyon, HC Kim, HM Kuerer, II Wistuba, J Czernin, JB Nikas, JPB O’Connor, K Brindle, K Sikora, K Suzuki, KA Wear, KM Brindle, KN Ogston, L Sannachi, LX Yao, M Dowsett, M Vaidya, MF Insana, ML Oelze, ML Oelze, N Duric, O Falou, O Falou, QH Huang, R Tiling, RM Haralick, RM Vlad, RM Vlad, SH Giordano, SH Giordano, SJ Cleator, SM Scholl, T Cover, TJ Larkin, U McDermott, V Goh, V Guarneri, X Li, Y Labyed   +70 more
core   +2 more sources

Neoadjuvant therapy for pancreatic cancer

British Journal of Surgery, 2007
No good evidence of benefit—trials ...
Jörg Kleeff, Helmut Friess, M.W. Büchler   +2 more
openaire   +2 more sources